KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Merck (MRK) over the last 17 years, with Q3 2025 value amounting to $18.2 billion.

  • Merck's Cash & Equivalents rose 2450.49% to $18.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 billion, marking a year-over-year increase of 2450.49%. This contributed to the annual value of $13.2 billion for FY2024, which is 9356.82% up from last year.
  • Per Merck's latest filing, its Cash & Equivalents stood at $18.2 billion for Q3 2025, which was up 2450.49% from $8.0 billion recorded in Q2 2025.
  • In the past 5 years, Merck's Cash & Equivalents registered a high of $18.2 billion during Q3 2025, and its lowest value of $5.6 billion during Q1 2024.
  • Its 5-year average for Cash & Equivalents is $9.8 billion, with a median of $8.6 billion in 2025.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 4610.84% in 2023, then soared by 9971.73% in 2024.
  • Over the past 5 years, Merck's Cash & Equivalents (Quarter) stood at $8.1 billion in 2021, then surged by 56.79% to $12.7 billion in 2022, then plummeted by 46.11% to $6.8 billion in 2023, then surged by 93.57% to $13.2 billion in 2024, then surged by 37.21% to $18.2 billion in 2025.
  • Its Cash & Equivalents was $18.2 billion in Q3 2025, compared to $8.0 billion in Q2 2025 and $8.6 billion in Q1 2025.